https://www.selleckchem.com/pr....oducts/wy-14643-piri
c acid levels and improved patients' DO profiles. These results highlight the importance of this new drug and its possible benefit with regard to myocardial injury; however, evaluation in larger, adequately powered trials is needed to determine the efficacy of levosimendan. Trial registry number EudraCT 2012-005310-19. Levosimendan does not significantly improve patients' postoperative troponin I and B-type natriuretic peptide profiles during the immediate postoperative stage in comparison with placebo, although both wer
Like
Comment
Share
